Key Metrics of ImmunityBio
Revenue$622K▲ 159.2% YoYFY 2023
Operating income−$362M▼ 3.1% YoY
Net profit−$584M▼ 39.9% YoY
Shareholders' equity−$587M
Market cap$9.2BIBRX · $8.64
Competitors10identified
About ImmunityBio
Part of NantWorks.
Sectors
Company details
- Website
- immunitybio.com
- Founded
- 2015
- Listed
- Nasdaq: IBRX (since 2015)
Operational Areas of ImmunityBio
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameImmunityBio Inc.
TickerIBRX
ExchangeNasdaq
CountryUnited States
SEC CIK0001326110
Listed since2015
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttp://immunitybio.com
US market & SEC filings
IBRX · Nasdaq · SEC CIK 0001326110
Last price · 22 Oct 2026
$8.64
−1.48%
Market cap$9.2B
P/E—On FY 2023 diluted EPS
Volume11,509,883
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited StatesListed 2015
IBRX share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeEl Segundo
GSTIN—
Email—
Websitehttp://immunitybio.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of ImmunityBio
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Group companies
Part of NantWorks
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.